Clinical Trials Logo
  1. Home
  2. Rhinoconjunctivitis
  3. NCT02849210

A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Rhinoconjunctivitis Clinical Trial

Official title:
A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Clinical Trial Summary

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Olea europaea pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity

Clinical Trial Description

An study conducted througout Spain with 4000 allergic patients (Alergoloógica 2005) showed that 47% of patients with rhinoconjuncitivits and 51% of asthmatic patients were sentitized to olive pollen. This gives us an idea of the importance of this allergen sensitization in Spain. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02849210
Study type Interventional
Source Roxall Medicina España S.A
Contact
Status Completed
Phase Phase 1
Start date September 2015
Completion date June 2, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05560698 - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment N/A
Completed NCT02340130 - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma Phase 2
Completed NCT02150343 - Phase II HDM-SPIRE Safety and Efficacy Study Phase 2
Completed NCT01923792 - ToleroMune House Dust Mite Follow on Study N/A
Completed NCT01949428 - House Dust Mite Observational Study N/A
Completed NCT01949415 - An Optional Investigation of Biomarkers of Efficacy N/A
Completed NCT01949441 - ToleroMune House Dust Mite (HDM) Tolerability Study Phase 2
Completed NCT01447784 - ToleroMune House Dust Mites (HDM) Exposure Chamber Study Phase 2
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT01620762 - Phase III Cat-PAD Study Phase 3
Completed NCT01720251 - Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy Phase 2
Completed NCT01448603 - ToleroMune Ragweed Follow up Study N/A
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00540631 - Multicenter Trial of Immunotherapy With House Dust Mite Allergoid Phase 3
Completed NCT00537342 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT) Phase 3
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT05540717 - Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Phase 3
Completed NCT02844842 - Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Completed NCT01734265 - Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml). Phase 2